查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
药物输送聚合物市场 - 2023-2028 年预测
市场调查报告书
商品编码
1295334

药物输送聚合物市场 - 2023-2028 年预测

Drug Delivery Polymer Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

药物输送聚合物市场预计复合年增长率为 7.55%，从 2021 年的 182.9 亿美元增长到 2028 年的 304.44 亿美元。

聚合物能够长时间以固定剂量控制释放药物，从而在改善药物输送方法方面发挥着重要作用。 由于其生物可降解性和生物相容性，近年来其在生物医学应用中的使用有所增加。 然而，使用聚合物作为药物载体提出了重大挑战，包括复杂的製造和表征步骤。 生物製药领域重要的是基于聚合物的药物递送，其中药物、蛋白质和抗体共价连接到线性或支化聚合物上。

此外，由于纳米技术领域的研发活动增加，以创造新的纳米药物、产品管道的扩大、有利的研究环境以及癌症和糖尿病等慢性疾病的患病率不断增加，药物输送聚合物市场预计将增长在整个预测期内增长。 然而，由于药物研究成本上升和严格的监管环境，预计市场在整个预测期内将面临挑战。

慢性疾病患病率的上升推动了药物输送聚合物市场的发展。

全球疾病的增加预计将增加对安全高效的给药系统的需求。 癌症、糖尿病和心血管疾病等自身免疫性疾病的日益流行预计将显着增加对可用于药物输送系统的聚合物的需求。 例如，世界卫生组织（WHO）估计，癌症将成为2020年全球约1000万人死亡的主要原因，全球确诊的男性癌症患者为9,342,957人，占癌症患者的15.4%。 与此同时，根据世界癌症研究基金会的数据，2020 年将有 8,751,759 名女性被诊断出患有癌症。

市场趋势：

  • Phosphorex 和 Dolomite Microfluidics 于 2021 年 6 月合作，结合双方在疫苗和药物开发方面的专业知识。 此次合作的目标是创建聚合物和脂质纳米颗粒。
  • 2022 年 4 月，CD Bioarticles 宣布推出多种藻酸盐产品以支持药物输送研究。 它们可以用胺基修饰或用生物素标记，仅供实验室使用。 藻酸盐是由线性共聚物和古洛醣醛酸单元形成的天然聚合物。
  • 2022 年3 月，赢创宣布推出EUDRATEC，其中包括EUDRAGIT 功能性聚合物等口服辅料、即装型功能胶囊EUDRACAPTM 以及增强药物性能的技术和服务。推出了SoluFlow，补充了赢创医疗保健的口服辅料组合药物输送系统解决方案。

北美在2021年全球药物输送聚合物市场中占有很大份额。

药物输送聚合物市场按地区分为北美、南美、欧洲、中东/非洲和亚太地区。

美国癌症、糖尿病和心血管疾病等慢性病的患病率很高，这增加了对先进药物输送系统的需求。 使用药物递送聚合物可以提高药物的生物利用度、减少副作用并提高患者的依从性。 美国政府还通过各种举措推广先进的药物输送系统，包括《21 世纪治愈法案》和 FDA 的快速严重疾病计划。 这些举措简化了创新药物输送系统的监管审批流程，使公司更容易将新产品推向市场。 此外，药物输送技术的重大进步，例如生物可降解聚合物、基于纳米技术的药物输送系统和控释製剂的开发，正在提高药物的功效和安全性。 这些创新有助于扩大使用基于聚合物的药物输送系统可输送的药物范围。

对自我给药的需求不断增长，导致了易于使用的药物输送系统的开发，例如吸入器、注射器和透皮贴剂，这些系统可以提高患者的依从性，并通过减少住院次数来降低医疗费用。曾是。 此外，对药物输送系统研发活动的大量投资预计将促进创新并将新产品推向市场。

内容

第 1 章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场细分
  • 货币
  • 先决条件
  • 基准年和预测年的时间表

第 2 章研究方法

  • 调查数据
  • 调查过程

第 3 章执行摘要

  • 研究亮点

第 4 章市场动态

  • 市场促进因素
  • 市场抑制因素
  • 波特五力分析
  • 行业价值链分析

第 5 章药物输送聚合物市场：按材料类型

  • 简介
  • PLGA（乳酸乙醇酸共聚物）
  • PGA（聚-L-谷氨酸）
  • 聚乳酸（可生物降解）
  • 温度响应聚合物
  • 有机聚合物
  • 其他

第 6 章药物输送聚合物市场：按药物输送应用划分

  • 简介
  • 扩散有限
  • 溶剂活化
  • 生物降解性/化学控制
  • 外部触发因素（pH 值、温度等）

第 7 章药物输送聚合物市场：按最终用户划分

  • 简介
  • 学术研究所
  • 医院
  • 製药公司

第 8 章药物输送聚合物市场：按地区

  • 简介
  • 北美
    • 按材料类型
    • 按药物输送应用
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按材料类型
    • 按药物输送应用
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按材料类型
    • 按药物输送应用
    • 按最终用户
    • 按国家/地区
  • 中东和非洲
    • 按材料类型
    • 按药物输送应用
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按材料类型
    • 按药物输送应用
    • 按最终用户
    • 按国家/地区

第 9 章竞争格局与分析

  • 主要公司及战略分析
  • 新兴公司和市场盈利能力
  • 併购 (M&A)、合同、合作
  • 供应商竞争力矩阵

第 10 章公司简介

  • Adhex Pharma
  • Chempilots a/s
  • Bezwada Biomedical, LLC.
  • POLYVATION BV
  • Poly-Med, Inc.
  • Henkel Corporation
  • Evonik Industries AG
  • ULTROXA（R）Polymers
  • IBMM/PHBM
  • Serina Therapeutics
  • The Lubrizol Corporation
简介目录
Product Code: KSI061612193

The drug delivery polymer market is predicted to grow at a CAGR of 7.55% from US$18.290 billion in 2021 to US$30.444 billion by 2028.

Polymers have played an important part in improving drug delivery methods by allowing for the controlled release of medications in regular doses over lengthy periods. Due to their biodegradability and biocompatibility, these have been increasingly used in biomedical applications in recent years. However, using polymers as carriers of drugs has significant difficulties, such as complex manufacturing and characterization processes. An important aspect of the biopharmaceutical sector is polymer-based drug delivery, in which a drug, protein, or antibody is covalently bonded to a linear or branched-chain polymer.

Further, the market for drug delivery polymer is anticipated to experience growth throughout the forecast period due to rising research and development activities in the field of nanotechnology to create novel nano-medicines, an expanding product pipeline, a favorable research environment, and an increase in the prevalence of chronic diseases like cancer and diabetes mellitus. However, the market is projected to face challenges throughout the forecast period due to high pharmaceutical research costs and strict regulatory environments.

The drug delivery polymer market is driven by the rising prevalence of chronic diseases.

The rising prevalence of diseases worldwide is anticipated to result in a growing demand for secure and efficient drug-delivery systems. There is expected to be a significant increase in demand for polymers that can be used in drug delivery systems due to the increased prevalence of autoimmune diseases such as cancer, diabetes, and cardiovascular disease. For instance, the World Health Organisation estimates that cancer will be the primary cause of roughly 10 million deaths worldwide in 2020, with which cancer cases in men were 9,342,957 contributing to 15.4% of the global cancer cases diagnosed. In contrast, females were diagnosed with 8,751,759 cancer cases in 2020, as per World Cancer Research Fund International.

Market Developments:

  • Phosphorex and Dolomite Microfluidics partnered in June 2021 to combine their expertise in developing vaccines and medications. The partnership's goal is to create polymeric nanoparticles and lipid nanoparticles.
  • CD Bioparticles announced several alginates products in April 2022 to support drug delivery research. They can be modified with amine groups or marked with biotin and are only meant for use in laboratory research. Alginates are naturally occurring polymers formed of linear copolymers and guluronic acid units.
  • In March 2022, Evonik launched EUDRATEC® SoluFlow, which contains oral excipients such as EUDRAGIT® functional polymers, the ready-to-fill functional capsules EUDRACAPTM, along with technologies and services to enhance drug performance, which complements the Evonik Health Care portfolio of oral drug delivery system solutions.

North America accounted for a major share of the global drug delivery polymer market in 2021.

The drug delivery polymer market has been segmented by geography into North America, South America, Europe, Middle East and Africa, and Asia Pacific.

The USA has a high prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases, which has led to an increased demand for advanced drug delivery systems. Using drug-delivery polymers helps improve the bioavailability of drugs, reduces side effects, and enhances patient compliance. Also, the US government has been promoting advanced drug delivery systems through various initiatives, such as the 21st Century Cures Act and the FDA's Expedited Programs for Serious Conditions. These initiatives have streamlined the regulatory approval process for innovative drug delivery systems, making it easier for companies to bring new products to market. Moreover, there have been significant advancements in drug delivery technologies, such as the development of biodegradable polymers, nanotechnology-based drug delivery systems, and controlled-release formulations, which have improved the efficacy and safety of drugs. These innovations have helped to expand the range of drugs that can be delivered using polymer-based drug delivery systems.

The growing demand for self-administration of drugs has resulted in the development of user-friendly drug delivery systems such as inhalers, injectors, and transdermal patches, which have improved patient compliance and reduced healthcare costs by decreasing hospitalization. Furthermore, significant investments in research and development activities focused on drug delivery systems are expected to drive innovation and bring new products to market.

Market Segmentation:

BY MATERIAL TYPE

  • PLGA (Polylactic-co-glycolic acid)
  • PGA (Poly-l-glutamic acid)
  • Polylactic acid (Biodegradable)
  • Temperature-responsive polymer
  • Organic polymer
  • Others

BY DRUG DELIVERY APPLICATION

  • Diffusion-controlled
  • Solvent activated
  • Biodegradable or chemically controlled
  • Externally triggered (i.e., pH, temperature, etc.)

BY END-USER

  • Academic and Research Institutes
  • Hospitals
  • Pharmaceutical Companies

BY GEOGRAPHY

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. DRUG DELIVERY POLYMER MARKET, BY MATERIAL TYPE

  • 5.1. Introduction
  • 5.2. PLGA (Polylactic-co-glycolic acid)
  • 5.3. PGA (Poly-l-glutamic acid)
  • 5.4. Polylactic acid (Biodegradable)
  • 5.5. Temperature-responsive polymer
  • 5.6. Organic polymer
  • 5.7. Others

6. DRUG DELIVERY POLYMER MARKET, BY DRUG DELIVERY APPLICATION

  • 6.1. Introduction
  • 6.2. Diffusion-controlled
  • 6.3. Solvent activated
  • 6.4. Biodegradable or chemically controlled
  • 6.5. Externally triggered (i.e., pH, temperature, etc.)

7. DRUG DELIVERY POLYMER MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Academic and Research Institutes
  • 7.3. Hospitals
  • 7.4. Pharmaceutical Companies

8. DRUG DELIVERY POLYMER MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Material Type
    • 8.2.2. By Drug Delivery Application
    • 8.2.3. By End User
    • 8.2.4. By Country
    • 8.2.4.1. United States
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Material Type
    • 8.3.2. By Drug Delivery Application
    • 8.3.3. By End User
    • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Material Type
    • 8.4.2. By Drug Delivery Application
    • 8.4.3. By End User
    • 8.4.4. By Country
    • 8.4.4.1. Germany
    • 8.4.4.2. France
    • 8.4.4.3. United Kingdom
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Material Type
    • 8.5.2. By Drug Delivery Application
    • 8.5.3. By End User
    • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. Israel
    • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Material Type
    • 8.6.2. By Drug Delivery Application
    • 8.6.3. By End User
    • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. Japan
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Adhex Pharma
  • 10.2. Chempilots a/s
  • 10.3. Bezwada Biomedical, LLC.
  • 10.4. POLYVATION BV
  • 10.5. Poly-Med, Inc.
  • 10.6. Henkel Corporation
  • 10.7. Evonik Industries AG
  • 10.8. ULTROXA® Polymers
  • 10.9. IBMM/PHBM
  • 10.10. Serina Therapeutics
  • 10.11. The Lubrizol Corporation